p-pbpk model Search Results


pbpk simulator version 21  (Certara L.P)
86
Certara L.P pbpk simulator version 21
Workflow for developing the escitalopram <t>PBPK</t> model. Upward arrows denote an increase, and downward arrows denote a decrease. Abbreviations: M.W., molecular weight; LogP, logarithm of octanol/water partition coefficient; pK a , negative logarithm of acid dissociation constant; B/P, blood-to-plasma ratio; fa, fraction absorbed; k a , absorption rate constant; f u,gut , fraction unbound in gut enterocytes; Q gut , Hybrid parameter representing drug absorption rate from the gut lumen, removal of drug from the enterocyte by enterocytic blood supply, and enterocyte volume; Vss, steady-state volume of distribution; K p scalar, tissue-to-plasma partition coefficient scalar; CL int , intrinsic clearance; CYP, cytochrome P450; GFR, glomerular filtration rate; NM, normal metabolizer; PM, poor metabolizer; CL PDM , Maternal-placental barrier clearance; CL PDF , placental-fetal barrier clearance.
Pbpk Simulator Version 21, supplied by Certara L.P, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p-pbpk+model/modelling+pbpk/pmc12567279-79-9-14
Average 86 stars, based on 1 article reviews
pbpk simulator version 21 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


Workflow for developing the escitalopram PBPK model. Upward arrows denote an increase, and downward arrows denote a decrease. Abbreviations: M.W., molecular weight; LogP, logarithm of octanol/water partition coefficient; pK a , negative logarithm of acid dissociation constant; B/P, blood-to-plasma ratio; fa, fraction absorbed; k a , absorption rate constant; f u,gut , fraction unbound in gut enterocytes; Q gut , Hybrid parameter representing drug absorption rate from the gut lumen, removal of drug from the enterocyte by enterocytic blood supply, and enterocyte volume; Vss, steady-state volume of distribution; K p scalar, tissue-to-plasma partition coefficient scalar; CL int , intrinsic clearance; CYP, cytochrome P450; GFR, glomerular filtration rate; NM, normal metabolizer; PM, poor metabolizer; CL PDM , Maternal-placental barrier clearance; CL PDF , placental-fetal barrier clearance.

Journal: Pharmaceutics

Article Title: Escitalopram Dose Optimization During Pregnancy: A PBPK Modeling Approach

doi: 10.3390/pharmaceutics17101341

Figure Lengend Snippet: Workflow for developing the escitalopram PBPK model. Upward arrows denote an increase, and downward arrows denote a decrease. Abbreviations: M.W., molecular weight; LogP, logarithm of octanol/water partition coefficient; pK a , negative logarithm of acid dissociation constant; B/P, blood-to-plasma ratio; fa, fraction absorbed; k a , absorption rate constant; f u,gut , fraction unbound in gut enterocytes; Q gut , Hybrid parameter representing drug absorption rate from the gut lumen, removal of drug from the enterocyte by enterocytic blood supply, and enterocyte volume; Vss, steady-state volume of distribution; K p scalar, tissue-to-plasma partition coefficient scalar; CL int , intrinsic clearance; CYP, cytochrome P450; GFR, glomerular filtration rate; NM, normal metabolizer; PM, poor metabolizer; CL PDM , Maternal-placental barrier clearance; CL PDF , placental-fetal barrier clearance.

Article Snippet: The PBPK model of escitalopram was developed using Simcyp ® PBPK simulator version 21 (Certara, Princeton, NJ, USA) to simulate pharmacokinetics in nonpregnant women, pregnant women, and the fetoplacental unit. shows the overall workflow.

Techniques: Molecular Weight, Clinical Proteomics, Filtration